MitoQ & Cardiopulmonary Responses During Exercise

NCT ID: NCT06069245

Last Updated: 2023-10-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-14

Study Completion Date

2023-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study Purpose: To examine the acute effects of antioxidant supplementation on energy use during a single bout of exercise in apparently healthy adult men and women.

Specifically this study examined the acute effect of MitoQ on:

1. cardiopulmonary responses to submax and maximal exercise
2. Energy expenditure and fat/carbohydrate oxidation during sub maximal exercise.

In a double-blind, randomized, placebo controlled, cross-over study design, participants performed 2 experimental trials which differed only in the supplement consumed (MitoQ or Placebo). Participants performed identical exercise protocols which consisted of a series of submaximal workloads followed by a ramp protocol to volitional exhaustion.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants performed the following 3 study visits:

Visit 1 consisted of baseline resting measures including blood pressure and blood vessel health, blood biomarkers, and body composition assessments.

Visits 2 and 3 were the acute supplementation intervention(s) with either MitoQ or Placebo in a randomly designed order. These visits included an assessment of blood pressure and blood vessel health and an exercise test on a stationary cycle. There was a minimum of 48-72 hours between trials 2 and 3.

Visit 1

* Participants arrived at the laboratory fasted from all food and drink other than water for at least 12 hours. The following assessments were performed:
* Informed consent and health history questionnaire
* Resting heart rate, handgrip strength, and body composition
* Resting electrocardiogram (ECG)
* Blood biomarkers (Total cholesterol, HDL, LDL-C, and triglycerides as well as fasting blood glucose and HbA1c).
* Blood pressure

Visit 2 \& 3 (performed in a randomized order differing only in the supplement consumed)

Acute supplementation intervention(s)

* The night before both the Placebo and MitoQ trials, participants were asked to eat the same meal at the same time of night and were provided with a standard Ensure shake to consume at 8:00pm the night before each trial.
* Upon arrival, they rested supine for \~10 minutes before consuming supplement (MitoQ or Placebo)
* Following consumption of the supplement or placebo, participants completed a graded aerobic exercise protocol. This test involved riding on a stationary cycle to exhaustion. The total test duration was \~30-45 minutes which included a break to rest between the submax and maximal portions. Heart function was monitored with an electrocardiogram (ECG). A gas analysis cart was used to determine the composition of the air breathed in and out during the test for the determination of substrate oxidation rates and VO2max. Heart rate was measured continuously throughout the exercise protocol from the ECG. Rate of perceived exertion (RPE) was measured every minute and blood pressure (BP) was performed every third minute of the exercise protocol. Additional measures of blood lactate via a finger stick were performed during the exercise protocol.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Double blind randomized placebo controlled crossover design
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Gelatin capsules

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Gelatin capsules

MitoQ

Commercially available MitoQ (80mg)

Group Type EXPERIMENTAL

MitoQ

Intervention Type DIETARY_SUPPLEMENT

80mg of MitoQ taken in one dose on one occasion.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MitoQ

80mg of MitoQ taken in one dose on one occasion.

Intervention Type DIETARY_SUPPLEMENT

Placebo

Gelatin capsules

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be greater than or equal to 18 years of age
* Have a resting seated systolic blood pressure (SBP) of less than 160 mmHg and diastolic blood pressure (DBP) less than 100 mmHg
* Nonsmoker
* Body mass index (BMI) less than or equal to 35 kg/m2
* Considered physically inactive defined as participating in \<150 min/week of moderate physical activity or \<75 minutes/week of vigorous activity (ACSM).

Exclusion Criteria

* participants that cannot complete the exercise protocol or have any signs/symptoms suggestive of cardiovascular or metabolic disease.
* Individuals that are currently on beta blockers
* diagnosed with type II diabetes will be excluded.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ball State University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ball State University

Muncie, Indiana, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1946841-3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

NR Supplementation and Exercise
NCT04907110 COMPLETED NA